213 related articles for article (PubMed ID: 24448822)
1. Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.
Fu M; Maresh EL; Helguera GF; Kiyohara M; Qin Y; Ashki N; Daniels-Wells TR; Aziz N; Gordon LK; Braun J; Elshimali Y; Soslow RA; Penichet ML; Goodglick L; Wadehra M
Mol Cancer Ther; 2014 Apr; 13(4):902-15. PubMed ID: 24448822
[TBL] [Abstract][Full Text] [Related]
2. EMP2 Is a Novel Regulator of Stemness in Breast Cancer Cells.
Dillard C; Kiyohara M; Mah V; McDermott SP; Bazzoun D; Tsui J; Chan AM; Haddad G; Pellegrini M; Chang YL; Elshimali Y; Wu Y; Vadgama JV; Kim SR; Goodglick L; Law SM; Patel DD; Dhawan P; O'Brien NA; Gordon LK; Braun J; Lazar G; Wicha MS; Wadehra M
Mol Cancer Ther; 2020 Aug; 19(8):1682-1695. PubMed ID: 32451329
[TBL] [Abstract][Full Text] [Related]
3. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
Fu M; Maresh EL; Soslow RA; Alavi M; Mah V; Zhou Q; Iasonos A; Goodglick L; Gordon LK; Braun J; Wadehra M
Clin Cancer Res; 2010 Aug; 16(15):3954-63. PubMed ID: 20670949
[TBL] [Abstract][Full Text] [Related]
4. Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells.
Filipović A; Lombardo Y; Faronato M; Abrahams J; Aboagye E; Nguyen QD; d'Aqua BB; Ridley A; Green A; Rahka E; Ellis I; Recchi C; Przulj N; Sarajlić A; Alattia JR; Fraering P; Deonarain M; Coombes RC
Breast Cancer Res Treat; 2014 Nov; 148(2):455-62. PubMed ID: 25248409
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.
Wang-Johanning F; Rycaj K; Plummer JB; Li M; Yin B; Frerich K; Garza JG; Shen J; Lin K; Yan P; Glynn SA; Dorsey TH; Hunt KK; Ambs S; Johanning GL
J Natl Cancer Inst; 2012 Feb; 104(3):189-210. PubMed ID: 22247020
[TBL] [Abstract][Full Text] [Related]
6. EMP2 is a novel therapeutic target for endometrial cancer stem cells.
Kiyohara MH; Dillard C; Tsui J; Kim SR; Lu J; Sachdev D; Goodglick L; Tong M; Torous VF; Aryasomayajula C; Wang W; Najafzadeh P; Gordon LK; Braun J; McDermott S; Wicha MS; Wadehra M
Oncogene; 2017 Oct; 36(42):5793-5807. PubMed ID: 28604744
[TBL] [Abstract][Full Text] [Related]
7. Diabodies targeting epithelial membrane protein 2 reduce tumorigenicity of human endometrial cancer cell lines.
Shimazaki K; Lepin EJ; Wei B; Nagy AK; Coulam CP; Mareninov S; Fu M; Wu AM; Marks JD; Braun J; Gordon LK; Wadehra M
Clin Cancer Res; 2008 Nov; 14(22):7367-77. PubMed ID: 19010852
[TBL] [Abstract][Full Text] [Related]
8. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
9. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
[TBL] [Abstract][Full Text] [Related]
10. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
11. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
12. Epithelial membrane protein-2 (EMP2) activates Src protein and is a novel therapeutic target for glioblastoma.
Qin Y; Fu M; Takahashi M; Iwanami A; Kuga D; Rao RG; Sudhakar D; Huang T; Kiyohara M; Torres K; Dillard C; Inagaki A; Kasahara N; Goodglick L; Braun J; Mischel PS; Gordon LK; Wadehra M
J Biol Chem; 2014 May; 289(20):13974-85. PubMed ID: 24644285
[TBL] [Abstract][Full Text] [Related]
13. Targeting claudin-4 enhances chemosensitivity in breast cancer.
Luo Y; Kishi S; Sasaki T; Ohmori H; Fujiwara-Tani R; Mori S; Goto K; Nishiguchi Y; Mori T; Kawahara I; Kondoh M; Kuniyasu H
Cancer Sci; 2020 May; 111(5):1840-1850. PubMed ID: 32086991
[TBL] [Abstract][Full Text] [Related]
14. CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.
Wang X; Osada T; Wang Y; Yu L; Sakakura K; Katayama A; McCarthy JB; Brufsky A; Chivukula M; Khoury T; Hsu DS; Barry WT; Lyerly HK; Clay TM; Ferrone S
J Natl Cancer Inst; 2010 Oct; 102(19):1496-512. PubMed ID: 20852124
[TBL] [Abstract][Full Text] [Related]
15. Positron emission tomography imaging of endometrial cancer using engineered anti-EMP2 antibody fragments.
Fu M; Brewer S; Olafsen T; Wu AM; Gordon LK; Said J; Braun J; Wadehra M
Mol Imaging Biol; 2013 Feb; 15(1):68-78. PubMed ID: 22585360
[TBL] [Abstract][Full Text] [Related]
16. MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer.
Greer YE; Gilbert SF; Gril B; Narwal R; Peacock Brooks DL; Tice DA; Steeg PS; Lipkowitz S
Breast Cancer Res; 2019 Feb; 21(1):27. PubMed ID: 30777098
[TBL] [Abstract][Full Text] [Related]
17. Novel antibody reagents for characterization of drug- and tumor microenvironment-induced changes in epithelial-mesenchymal transition and cancer stem cells.
Navas T; Pfister TD; Colantonio S; Aziz A; Dieckman L; Saul RG; Kaczmarczyk J; Borgel S; Alcoser SY; Hollingshead MG; Lee YH; Bottaro DP; Hiltke T; Whiteley G; Takebe N; Kinders RJ; Parchment RE; Tomaszewski JE; Doroshow JH
PLoS One; 2018; 13(6):e0199361. PubMed ID: 29928062
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
19. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
20. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP.
Hiyoshi H; Goto N; Tsuchiya M; Iida K; Nakajima Y; Hirata N; Kanda Y; Nagasawa K; Yanagisawa J
Sci Rep; 2014 Nov; 4():7095. PubMed ID: 25403352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
